348 related articles for article (PubMed ID: 12384518)
21. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
[TBL] [Abstract][Full Text] [Related]
22. Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis.
Yan H; Frost P; Shi Y; Hoang B; Sharma S; Fisher M; Gera J; Lichtenstein A
Cancer Res; 2006 Feb; 66(4):2305-13. PubMed ID: 16489035
[TBL] [Abstract][Full Text] [Related]
23. Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex.
Tarasewicz A; Debska-Slizień A; Konopa J; Zdrojewski Z; Rutkowski B
Transplant Proc; 2009 Nov; 41(9):3677-82. PubMed ID: 19917366
[TBL] [Abstract][Full Text] [Related]
24. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent.
Jaeschke A; Hartkamp J; Saitoh M; Roworth W; Nobukuni T; Hodges A; Sampson J; Thomas G; Lamb R
J Cell Biol; 2002 Oct; 159(2):217-24. PubMed ID: 12403809
[TBL] [Abstract][Full Text] [Related]
25. mTOR cascade activation distinguishes tubers from focal cortical dysplasia.
Baybis M; Yu J; Lee A; Golden JA; Weiner H; McKhann G; Aronica E; Crino PB
Ann Neurol; 2004 Oct; 56(4):478-87. PubMed ID: 15455405
[TBL] [Abstract][Full Text] [Related]
26. Distinct effects of single amino-acid changes to tuberin on the function of the tuberin-hamartin complex.
Nellist M; Sancak O; Goedbloed MA; Rohe C; van Netten D; Mayer K; Tucker-Williams A; van den Ouweland AM; Halley DJ
Eur J Hum Genet; 2005 Jan; 13(1):59-68. PubMed ID: 15483652
[TBL] [Abstract][Full Text] [Related]
27. Sirolimus and tuberous sclerosis-associated renal angiomyolipomas.
Krischock L; Beach R; Taylor J
Arch Dis Child; 2010 May; 95(5):391-2. PubMed ID: 20457704
[TBL] [Abstract][Full Text] [Related]
28. Tuberin, p27 and mTOR in different cells.
Burgstaller S; Rosner M; Lindengrün C; Hanneder M; Siegel N; Valli A; Fuchs C; Hengstschläger M
Amino Acids; 2009 Feb; 36(2):297-302. PubMed ID: 18386114
[TBL] [Abstract][Full Text] [Related]
29. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.
Roux PP; Ballif BA; Anjum R; Gygi SP; Blenis J
Proc Natl Acad Sci U S A; 2004 Sep; 101(37):13489-94. PubMed ID: 15342917
[TBL] [Abstract][Full Text] [Related]
30. The G1556S-type tuberin variant suppresses tumor formation in tuberous sclerosis 2 mutant (Eker) rats despite its deficiency in mTOR inhibition.
Shiono M; Kobayashi T; Takahashi R; Sun G; Abe M; Zhang D; Wang L; Piao X; Takagi Y; Mineki R; Taka H; Tada N; Sonobe S; Momose S; Ueda M; Hino O
Oncogene; 2008 Nov; 27(52):6690-7. PubMed ID: 18695678
[TBL] [Abstract][Full Text] [Related]
31. Acetaldehyde promotes rapamycin-dependent activation of p70(S6K) and glucose uptake despite inhibition of Akt and mTOR in dopaminergic SH-SY5Y human neuroblastoma cells.
Fang CX; Yang X; Sreejayan N; Ren J
Exp Neurol; 2007 Jan; 203(1):196-204. PubMed ID: 16962100
[TBL] [Abstract][Full Text] [Related]
32. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.
Tee AR; Fingar DC; Manning BD; Kwiatkowski DJ; Cantley LC; Blenis J
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13571-6. PubMed ID: 12271141
[TBL] [Abstract][Full Text] [Related]
33. Akt regulates nuclear/cytoplasmic localization of tuberin.
Rosner M; Freilinger A; Hengstschläger M
Oncogene; 2007 Jan; 26(4):521-31. PubMed ID: 16862180
[TBL] [Abstract][Full Text] [Related]
34. Tuberous sclerosis causing mutants of the TSC2 gene product affect proliferation and p27 expression.
Soucek T; Rosner M; Miloloza A; Kubista M; Cheadle JP; Sampson JR; Hengstschläger M
Oncogene; 2001 Aug; 20(35):4904-9. PubMed ID: 11521203
[TBL] [Abstract][Full Text] [Related]
35. Morphology of cerebral lesions in the Eker rat model of tuberous sclerosis.
Wenzel HJ; Patel LS; Robbins CA; Emmi A; Yeung RS; Schwartzkroin PA
Acta Neuropathol; 2004 Aug; 108(2):97-108. PubMed ID: 15185103
[TBL] [Abstract][Full Text] [Related]
36. Age dependence of radiation-induced renal cell carcinomas in an Eker rat model.
Kokubo T; Kakinuma S; Kobayashi T; Watanabe F; Iritani R; Tateno K; Nishimura M; Nishikawa T; Hino O; Shimada Y
Cancer Sci; 2010 Mar; 101(3):616-23. PubMed ID: 20132221
[TBL] [Abstract][Full Text] [Related]
37. Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation.
Uhlmann EJ; Li W; Scheidenhelm DK; Gau CL; Tamanoi F; Gutmann DH
Glia; 2004 Aug; 47(2):180-8. PubMed ID: 15185396
[TBL] [Abstract][Full Text] [Related]
38. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.
Chan JA; Zhang H; Roberts PS; Jozwiak S; Wieslawa G; Lewin-Kowalik J; Kotulska K; Kwiatkowski DJ
J Neuropathol Exp Neurol; 2004 Dec; 63(12):1236-42. PubMed ID: 15624760
[TBL] [Abstract][Full Text] [Related]
39. Restoration of Normal Cerebral Oxygen Consumption with Rapamycin Treatment in a Rat Model of Autism-Tuberous Sclerosis.
Chi OZ; Wu CC; Liu X; Rah KH; Jacinto E; Weiss HR
Neuromolecular Med; 2015 Sep; 17(3):305-13. PubMed ID: 26048361
[TBL] [Abstract][Full Text] [Related]
40. CDKs as therapeutic targets for the human genetic disease tuberous sclerosis?
Rosner M; Dolznig H; Fuchs C; Siegel N; Valli A; Hengstschläger M
Eur J Clin Invest; 2009 Dec; 39(12):1033-5. PubMed ID: 19744185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
